Online inquiry

IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11941MR)

This product GTTS-WQ11941MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets LTA gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000595.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4049
UniProt ID P01374
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11941MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15501MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA UCB-7665
GTTS-WQ15509MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-7665
GTTS-WQ6835MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ8384MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ8409MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HS006
GTTS-WQ9853MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA K7153A
GTTS-WQ6091MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ6563MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DC-1630423
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW